Keywords: further, promising, preclinical, data, oncolytics, reolysin, systemic
Further promising preclinical data for Oncolytics' Reolysin
Article | 10 August 2001
The systemic administration of Oncolytic Biotech's reovirus-basedReolysin is an effective monotherapy for the treatment of cancer in animal models that ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
